Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , appears to provide a significant development for obesity management . Early patient trials have shown https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide